| 摘要 |
<p>A cardiovascular composition is disclosed which comprises a dibenzo-thiepin compound having the formula <CHEM> wherein: X is a C1-C4 hydrocarbon group, optionally containing O, N or CO; Z is S, SO, SO2, CO, CR<4>R<5> wherein R<4> and R<5> taken together form the group =O or =CHR<6> wherein R<6> is hydrogen or phenyl; R<1> is, e.g., 5-tetrazolyl, 5-tetrazolylmethyl, and <CHEM> wherein m is an integer of from 0 to 4 and R<7> is, e.g., hydroxy or loweralkoxy; R<2> and R<3> can each independently be hydrogen, halogen (F, Cl, Br or I), nitro, loweralkyl, amino, N-loweralkylamino, N,N-diloweralkylamino, loweralkanoyl, hydroxy, loweralkoxy, lower acyloxy, loweralkylthio, trifluoromethylthio, loweralkylsulfinyl, loweralkylsulfonyl, trifluoromethyl, or R<2> and R<3>, when bonded to adjacent carbon atoms, can be joined to form a 5- or 6-membered hydrocarbon ring which can optionally contain a double bond, a carbonyl group, or a hydroxyl group; or a pharmaceutically acceptable salt thereof and an angiotensin converting enzyme (ACE) inhibitor. These compositions represent a novel therapeutic approach to thromboembolic diseases in man.</p> |
